WO2020185056A3 - 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제 - Google Patents
타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제 Download PDFInfo
- Publication number
- WO2020185056A3 WO2020185056A3 PCT/KR2020/095016 KR2020095016W WO2020185056A3 WO 2020185056 A3 WO2020185056 A3 WO 2020185056A3 KR 2020095016 W KR2020095016 W KR 2020095016W WO 2020185056 A3 WO2020185056 A3 WO 2020185056A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immune cell
- same
- culture obtained
- cells
- therapeutic agent
- Prior art date
Links
- 210000002865 immune cell Anatomy 0.000 title abstract 7
- 238000012258 culturing Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000000735 allogeneic effect Effects 0.000 title abstract 2
- 238000004113 cell culture Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0643—Osteoclasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/983—Blood, e.g. plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1157—Monocytes, macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Birds (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
본 발명은 면역요법에 적용되는 자연살해세포(Natural Killer cell; NK 세포) 배양방법에 관한 것으로, 보다 구체적으로는 면역세포치료제가 투여될 환자가 아니라 건강한 공여자의 혈액에서 유래된 림프구를 배양하여 악성종양 치료에 효과가 뛰어난 NK세포를 효율적으로 증폭 및 활성화시키는 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제에 대한 것이다.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080033852.4A CN113795573A (zh) | 2019-03-08 | 2020-03-05 | 培养同种异体免疫细胞的方法、用该方法获得的免疫细胞培养物和包含其的免疫细胞治疗剂 |
EP20769957.0A EP3967753A4 (en) | 2019-03-08 | 2020-03-05 | PROCESS FOR CULTIVATION OF ALLOGOUS IMMUNITY CELLS, IMMUNITY CELL CULTURE OBTAINED THEREBY AND IMMUNITY CELL THERAPEUTIC THEREFORE |
US17/437,140 US20220168348A1 (en) | 2019-03-08 | 2020-03-05 | Method for culturing allogeneic immune cell, immune cell culture obtained thereby, and immune cell therapeutic agent comprising same |
JP2021553758A JP2022524146A (ja) | 2019-03-08 | 2020-03-05 | 他家免疫細胞培養方法、その方法により得られた免疫細胞培養液、及びこれを含む免疫細胞治療剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0027152 | 2019-03-08 | ||
KR1020190027152A KR102234394B1 (ko) | 2019-03-08 | 2019-03-08 | 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2020185056A2 WO2020185056A2 (ko) | 2020-09-17 |
WO2020185056A3 true WO2020185056A3 (ko) | 2020-11-05 |
Family
ID=72426421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/095016 WO2020185056A2 (ko) | 2019-03-08 | 2020-03-05 | 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220168348A1 (ko) |
EP (1) | EP3967753A4 (ko) |
JP (1) | JP2022524146A (ko) |
KR (1) | KR102234394B1 (ko) |
CN (1) | CN113795573A (ko) |
WO (1) | WO2020185056A2 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6977969B2 (ja) * | 2019-03-22 | 2021-12-08 | 株式会社ガイアバイオメディシン | 免疫細胞提供システム |
CN116370619B (zh) * | 2022-04-02 | 2024-04-12 | 北京达尔文细胞生物科技有限公司 | 一种安全有效的同种异体免疫细胞组合物及其制备方法和其用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090127973A (ko) * | 2008-06-10 | 2009-12-15 | 주식회사 엔케이바이오 | 자기활성화 림프구 배양 방법 |
KR20130047167A (ko) * | 2011-10-31 | 2013-05-08 | 이동욱 | 면역세포 증식 배양액이 함유된 화장료 조성물 제조방법 |
KR20140043340A (ko) * | 2011-04-13 | 2014-04-09 | 이뮤니쿰 에이비 | T 세포의 프라이밍을 위한 방법 |
WO2018044809A1 (en) * | 2016-08-29 | 2018-03-08 | Hackensack University Medical Center | Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans |
KR20180057359A (ko) * | 2016-11-22 | 2018-05-30 | 신동혁 | 면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996029394A1 (en) * | 1995-03-17 | 1996-09-26 | The Regents Of The University Of California | Method for treating tumors |
US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
KR20120093978A (ko) * | 2009-10-27 | 2012-08-23 | 이뮤니쿰 에이비 | 항원 특이적 t 세포의 증식 방법 |
JP5572863B2 (ja) * | 2011-06-24 | 2014-08-20 | 国立大学法人九州大学 | Nk細胞の増幅方法 |
US20160046715A1 (en) * | 2013-05-17 | 2016-02-18 | Abwiz Bio, Inc. | T regulatory cells and uses thereof |
JP6073417B2 (ja) * | 2015-06-26 | 2017-02-01 | チャ バイオテック カンパニー リミテッド | 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物 |
KR101683614B1 (ko) * | 2016-02-15 | 2016-12-07 | 신동혁 | Nk세포배양용 배지첨가키트 및 상기 키트를 이용한 nk세포배양방법 |
JP2019031470A (ja) * | 2017-08-09 | 2019-02-28 | 株式会社再生医学研究所 | Nk細胞培養上清を含む抗腫瘍組成物およびその製造方法 |
-
2019
- 2019-03-08 KR KR1020190027152A patent/KR102234394B1/ko active IP Right Grant
-
2020
- 2020-03-05 CN CN202080033852.4A patent/CN113795573A/zh active Pending
- 2020-03-05 WO PCT/KR2020/095016 patent/WO2020185056A2/ko unknown
- 2020-03-05 US US17/437,140 patent/US20220168348A1/en active Pending
- 2020-03-05 JP JP2021553758A patent/JP2022524146A/ja active Pending
- 2020-03-05 EP EP20769957.0A patent/EP3967753A4/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090127973A (ko) * | 2008-06-10 | 2009-12-15 | 주식회사 엔케이바이오 | 자기활성화 림프구 배양 방법 |
KR20140043340A (ko) * | 2011-04-13 | 2014-04-09 | 이뮤니쿰 에이비 | T 세포의 프라이밍을 위한 방법 |
KR20130047167A (ko) * | 2011-10-31 | 2013-05-08 | 이동욱 | 면역세포 증식 배양액이 함유된 화장료 조성물 제조방법 |
WO2018044809A1 (en) * | 2016-08-29 | 2018-03-08 | Hackensack University Medical Center | Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans |
KR20180057359A (ko) * | 2016-11-22 | 2018-05-30 | 신동혁 | 면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물 |
Also Published As
Publication number | Publication date |
---|---|
WO2020185056A2 (ko) | 2020-09-17 |
JP2022524146A (ja) | 2022-04-27 |
EP3967753A2 (en) | 2022-03-16 |
KR102234394B1 (ko) | 2021-03-31 |
EP3967753A4 (en) | 2022-12-21 |
US20220168348A1 (en) | 2022-06-02 |
CN113795573A (zh) | 2021-12-14 |
KR20200107666A (ko) | 2020-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Oyer et al. | PD-L1 blockade enhances anti-tumor efficacy of NK cells | |
CN109294985B (zh) | 一种用于nk细胞体外扩增的培养基体系及nk细胞体外扩增的方法 | |
Hsu et al. | Prostaglandin E2 potentiates mesenchymal stem cell–induced IL-10+ IFN-γ+ CD4+ regulatory T cells to control transplant arteriosclerosis | |
Jewett et al. | NK cells shape pancreatic and oral tumor microenvironments; role in inhibition of tumor growth and metastasis | |
Miller et al. | Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy | |
KR101851270B1 (ko) | 자연 살해세포의 대량증식 방법 및 배양용 조성물 | |
CA2796379A1 (en) | Method for proliferation of antigen-specific t cells | |
CN103756963A (zh) | 一种体外扩增nk细胞的方法 | |
CN108676775B (zh) | 一种体外扩增脐血nk的方法 | |
JP2019520061A5 (ko) | ||
CN103648524A (zh) | 使用树突细胞和由高静水压力杀死的肿瘤细胞对癌症进行主动细胞免疫治疗的手段和方法 | |
WO2020185056A3 (ko) | 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제 | |
WO2020000035A8 (en) | Modified t cells and uses thereof | |
WO2019157158A3 (en) | Methods for allogenic hematopoietic stem cell transplantation | |
CN106148282A (zh) | 一种自然杀伤细胞的培养方法 | |
IL257929B1 (en) | Methods for the treatment of multiple myeloma and plasma cell leukemia using T-cell therapy | |
KR101968184B1 (ko) | 저산소 조건을 이용한 면역세포의 증식 배양 방법 | |
CN105219713A (zh) | 用于肿瘤过继性免疫的高增殖力、高杀伤力nk细胞 | |
CN105505871A (zh) | 一种有效扩增cik且提高其特异性杀瘤能力的方法 | |
CN105462926A (zh) | 一种免疫细胞瘤苗的制备方法及其应用 | |
CN103372029A (zh) | 肿瘤治疗用nk细胞新技术 | |
TW202206591A (zh) | 體外增殖自然殺手細胞及自然殺手t細胞之方法 | |
CN106822861A (zh) | 抗原肽gpc3‑1和gpc3‑3在制备治疗肝癌药物中的应用 | |
Har-Noy et al. | Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity | |
WO2021101273A3 (ko) | 조절 t 세포 배양용 조성물 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20769957 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2021553758 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020769957 Country of ref document: EP Effective date: 20211008 |